tiprankstipranks
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
US Market
Holding AXSM?
Track your performance easily

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

2,035 Followers
See the Price Targets and Ratings of:

AXSM Analyst Ratings

Strong Buy
15Ratings
15 Buy
0 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Axsome
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AXSM Stock 12 Month Forecast

Average Price Target

$137.36
▲(46.61% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $137.36 with a high forecast of $180.00 and a low forecast of $110.00. The average price target represents a 46.61% change from the last price of $93.69.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"72":"$72","181":"$181","99.25":"$99.3","126.5":"$126.5","153.75":"$153.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":137.36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$137.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$110.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[72,99.25,126.5,153.75,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Oct<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.61,91.94769230769231,99.28538461538461,106.62307692307692,113.96076923076923,121.29846153846154,128.63615384615383,135.97384615384615,143.31153846153848,150.64923076923077,157.98692307692306,165.32461538461538,172.6623076923077,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.61,88.6676923076923,92.72538461538461,96.78307692307692,100.84076923076924,104.89846153846153,108.95615384615385,113.01384615384616,117.07153846153847,121.12923076923077,125.18692307692308,129.2446153846154,133.3023076923077,{"y":137.36,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.61,86.56307692307692,88.51615384615384,90.46923076923076,92.4223076923077,94.37538461538462,96.32846153846154,98.28153846153846,100.23461538461538,102.18769230769232,104.14076923076922,106.09384615384616,108.04692307692308,{"y":110,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":77.06,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.45,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.42,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.99,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.89,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.43,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.03,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.86,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$180.00Average Price Target$137.36Lowest Price Target$110.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners
$110
Buy
17.41%
Upside
Reiterated
12/30/24
Axsome mixed agitation data creates 'most confusion,' says LeerinkAxsome mixed agitation data creates 'most confusion,' says Leerink
Guggenheim
$135
Buy
44.09%
Upside
Reiterated
12/30/24
Guggenheim reiterates Buy Rating on Axsome Therapeutics (AXSM)Guggenheim analyst Yatin Suneja reiterated a Buy rating and $135.00 price target on Axsome Therapeutics (NASDAQ: AXSM).
Bank of America Securities
$118
Buy
25.95%
Upside
Reiterated
12/30/24
Axsome AXS-05 ADA results supportive of approval, says BofAAxsome AXS-05 ADA results supportive of approval, says BofA
Wells Fargo
$140
Buy
49.43%
Upside
Reiterated
12/30/24
Positive Outlook for Axsome Therapeutics: AXS-05 Advances Despite Setbacks
Ladenburg Thalmann & Co.
$175
Buy
86.79%
Upside
Reiterated
11/27/24
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Madrigal Pharmaceuticals (MDGL)

Best Analysts Covering Axsome Therapeutics

Which Analyst Should I Follow If I Want to Buy AXSM and Sell After:
1 Month
xxx
Success Rate
15/22 ratings generated profit
68%
Average Return
+16.74%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 68.18% of your transactions generating a profit, with an average return of +16.74% per trade.
3 Months
xxx
Success Rate
15/22 ratings generated profit
68%
Average Return
+46.83%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.18% of your transactions generating a profit, with an average return of +46.83% per trade.
1 Year
Joon LeeTruist Financial
Success Rate
16/19 ratings generated profit
84%
Average Return
+41.73%
reiterated a buy rating 5 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +41.73% per trade.
2 Years
xxx
Success Rate
24/27 ratings generated profit
89%
Average Return
+23.97%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +23.97% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AXSM Analyst Recommendation Trends

Rating
Sep 24
Oct 24
Nov 24
Dec 24
Jan 25
Strong Buy
8
9
9
13
14
Buy
24
28
39
41
37
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
37
48
54
51
In the current month, AXSM has received 51 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AXSM average Analyst price target in the past 3 months is $137.36.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

AXSM Financial Forecast

AXSM Earnings Forecast

Next quarter’s earnings estimate for AXSM is -$0.96 with a range of -$1.47 to -$0.46. The previous quarter’s EPS was -$1.34. AXSM beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 55.77% of the time in the same period. In the last calendar year AXSM has Outperformed its overall industry.
Next quarter’s earnings estimate for AXSM is -$0.96 with a range of -$1.47 to -$0.46. The previous quarter’s EPS was -$1.34. AXSM beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 55.77% of the time in the same period. In the last calendar year AXSM has Outperformed its overall industry.

AXSM Sales Forecast

Next quarter’s sales forecast for AXSM is $117.65M with a range of $108.50M to $126.08M. The previous quarter’s sales results were $104.76M. AXSM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.15% of the time in the same period. In the last calendar year AXSM has Outperformed its overall industry.
Next quarter’s sales forecast for AXSM is $117.65M with a range of $108.50M to $126.08M. The previous quarter’s sales results were $104.76M. AXSM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.15% of the time in the same period. In the last calendar year AXSM has Outperformed its overall industry.

AXSM Stock Forecast FAQ

What is AXSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Axsome Therapeutics Inc’s 12-month average price target is $137.36.
    What is AXSM’s upside potential, based on the analysts’ average price target?
    Axsome Therapeutics Inc has 46.61% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AXSM a Buy, Sell or Hold?
          Axsome Therapeutics Inc has a consensus rating of Strong Buy which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Axsome Therapeutics Inc’s price target?
            The average price target for Axsome Therapeutics Inc is $137.36. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $180.00 ,the lowest forecast is $110.00. The average price target represents 46.61% Increase from the current price of $93.69.
              What do analysts say about Axsome Therapeutics Inc?
              Axsome Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of AXSM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis